ClinicalTrials.gov. ALEX Study: A Randomized, Phase III Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Patients. NCT02075840. https://clinicaltrials.gov/ct2/show/NCT02075840. Accessed June 15, 2015.
Aupérin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:2181-2190. Abstract
Bradley JD, Bae K, Graham MV, et al. Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117. J Clin Oncol. 2010;28:2475-2480. Abstract
Bradley JD, Paulus R, Graham MV, et al; Radiation Therapy Oncology Group. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group -- RTOG 9705. J Clin Oncol. 2005;23:3480-3487. Abstract
Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16:187-199. Abstract
Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990;323:940-945. Abstract
Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367:1694-1703. Abstract
Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol. 2014;15:1119-1128. Abstract
Gandhi L, Shaw A. Gadgeel SM, et al. A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an ALK+ non-small-cell lung cancer (NSCLC) U.S./Canadian population who had progressed on crizotinib (NP28761). J Clin Oncol. 2015;33. Abstract 8019.
Gadgeel SM, Ruckdeschel JC, Patel BB, et al. Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer. J Thorac Oncol. 2011;6:927-933. Abstract
Govindan R, Bogart J, Stinchcombe T, et al. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. J Clin Oncol. 2011;29:3120-3125. Abstract
Govindan R, Bogart J, Wang X, et al. A phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407 -- early evaluation of feasibility and toxicity. J Clin Oncol. 2008;26:7518.
Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006;24:2038-2043. Abstract
Jalal SI, Riggs HD, Melnyk A, et al. Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology. Ann Oncol. 2012;23:1730-1738. Abstract
Jänne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372:1689-1699. Abstract
Johnson DB, Flaherty KT, Weber JS, et al. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol. 2014;32:3697-3704. Abstract
Lara PN Jr, Chansky K, Shibata T, et al. Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124. Cancer. 2010;116:5710-5715. Abstract
Lara PN Jr, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009;27:2530-2535. Abstract
Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371:1877-1888. Abstract
Mok T, Spigel D, Felip E, et al. ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). J Clin Oncol. 2015;33. Abstract 8059.
Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-957. Abstract
Naito Y, Kubota K, Ohmatsu H, et al. Phase II study of nedaplatin and docetaxel in patients with advanced squamous cell carcinoma of the lung. Ann Oncol. 2011;22:2471-2475. Abstract
Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346:85-91. Abstract
Ou S-HI, Ahn JS, De Pretris L, et al. Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: an open-label, single-arm, global phase 2 study (NP28673). J Clin Oncol. 2015;33. Abstract 8008.
Park K, Lee J-S, Lee KH, et al. Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI). J Clin Oncol. 2015;33. Abstract 8084.
Paz-Ares L, Horn L, Borghaei H, et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous (non-SQ) cell non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33. Abstract LBA109.
Planchard D, Groen HJM, Kim TM, et al. Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33. Abstract 8006.
Planchard D, Kim T, Mazières J, et al. Dabrafenib in patients with BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC): A multicenter, open-label, phase II trial (BRF113928). Ann Oncol. 2014;25:1-41.
Planchard D, Mazieres J, Riely GJ, et al. Interim results of phase II study BRF113928 of dabrafenib in BRAFV600E mutation-positive non-small cell lung cancer (NSCLC) patients. J Clin Oncol. 2013;31. Abstract 8009.
Ramalingam SS, Rukazenkov Y, Thomas K, Soria J-C. A randomized, phase III study (FLAURA) of AZD9291, a novel EGFR-TKI, versus gefitinib or erlotinib in treatment-naïve patients with advanced non-small cell lung cancer and an EGFR-TKI-sensitizing mutation. J Clin Oncol. 2015;33. Abstract TPS8102.
Ramalingam SS, Yang JC, Lee CK, et al. AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): results from a phase 1 expansion cohort. J Clin Oncol. 2015;33. Abstract 8000.
Rizvi NA, Brahmer JR, Ou S-HI, et al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33. Abstract 8032.
Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30-39. Abstract
Rolfo C, Passiglia F, Ostrowski M, et al. Improvement in lung cancer outcomes with targeted therapies: an update for family physicians. J Am Board Fam Med. 2015;28:124-133. Abstract
Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239-246. Abstract
Scagliotti G, Brodowicz T, Shepherd FA, et al. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol. 2011;6:64-70. Abstract
Senan S, Brade AM, Wang L, et al. Final overall survival (OS) results of the phase III PROCLAIM trial: Pemetrexed (Pem), cisplatin (Cis) or etoposide (Eto), Cis plus thoracic radiation therapy (TRT) followed by consolidation cytotoxic chemotherapy (CTX) in locally advanced nonsquamous non-small cell lung cancer (nsNSCLC). J Clin Oncol. 2015;33. Abstract 7506.
Sequist LV, Goldman JW, Wakelee HA, et al. Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol. 2015;33. Abstract 8001.
Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3:75ra26.
Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:3327-3334. Abstract
Shukuya T, Yamanaka T, Seto T, et al. Randomized phase III study of nedaplatin (N) plus docetaxel (D) versus cisplatin (C) plus D for advanced or relapsed squamous cell carcinoma of the lung (SqLC): WJOG5208L. J Clin Oncol. 2015;33. Abstract 8004.
Spigel DR, Reckamp KL, Rizvi NA, et al. A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33. Abstract 8009.
Soria J-C, Felip E, Cobo M, et al. Afatinib (A) vs erlotinib (E) as second-line therapy of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following platinum-based chemotherapy: Overall survival (OS) analysis from the global phase III trial LUX-Lung 8 (LL8). J Clin Oncol. 2015;33. Abstract 8002.
Spira AI, Park K, Mazieres J, et al. Efficacy, safety and predictive biomarker results from a randomized phase II study comparing atezolizumab (MPDL3280A) vs docetaxel in 2L/3L NSCLC (POPLAR). J Clin Oncol. 2015;33. Abstract 8010.
Tan DS-W, Seto T, Leighl NB, et al. First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M. J Clin Oncol. 2015;33. Abstract 8013.
Teramoto K, Asada Y, Ozaki Y, et al. A phase II study of docetaxel plus nedaplatin in patients with metastatic non-small-cell lung cancer. Cancer Chemother Pharmacol. 2012;70:531-537. Abstract
Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19:2240-2247. Abstract
Yu HA, Oxnard GR, Spira AI, et al. Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC. J Clin Oncol. 2015;33. Abstract 8083.
Zatloukal P, Cardenal F, Szczesna A, et al. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol. 2010;21:1810-1816. Abstract

CME

New Horizons in Advanced Non-small Cell Lung Cancer: Highlights from Chicago

Authors: Suresh S. Ramalingam, MD; Giorgio V. Scagliotti, MD, PhD; Panagiotis Fidias, MD; Jared Weiss, MD; H. Jack West, MD; Hossein Borghaei, DO
CME Released: 6/22/2015
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 6/22/2016, 11:59 PM EST

Target Audience and Goal Statement

This activity is intended for oncologists, pulmonologists, pathologists, and other members of oncology care teams.

The goal of this activity is to review the latest clinical data as presented at the 2015 annual meeting of the American Society of Clinical Oncology (ASCO^®) for the treatment of patients with advanced non-small cell lung cancer (NSCLC).

Upon completion of this activity, participants will be able to:

Evaluate emerging agents that target regulation of the immune system and their potential role in the care of patients with advanced NSCLC
Detail the role of tumor characteristics including the use of histology, genotype, and protein expression in selecting treatment for patients with advanced NSCLC
Identify advances in the treatment of advanced NSCLC that has progressed on first-line therapy or become resistant to molecularly targeted therapy
Assess clinical trial data evaluating investigational agents for the treatment of advanced NSCLC presented at the ASCO^® 2015 Annual Meeting
Discuss how new data presented at the ASCO^® 2015 Annual Meeting on treatment strategies for advanced NSCLC might affect current standards in community practice

Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Authors

Suresh S. Ramalingam, MD

Professor of Hematology/Oncology; Director, Lung Cancer Program, Winship Cancer Institute, Emory University, Atlanta, Georgia

Disclosures

The opinions expressed are those of Dr Ramalingam and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Ramalingam's participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.

Disclosure: Suresh S. Ramalingam, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Genentech, Inc.; Lilly

Dr Ramalingam does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Ramalingam does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Giorgio V. Scagliotti, MD, PhD

Professor of Medical Oncology; Chief, Department of Oncology, University of Turin at San Luigi Hospital, Turin, Italy

Disclosures

Disclosure: Giorgio V. Scagliotti, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Lilly
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Clovis Oncology; Lilly; Pfizer Inc; Roche

Dr Scagliotti does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Scagliotti does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panagiotis Fidias, MD

Associate Professor of Medicine, Harvard Medical School; Member, Thoracic Oncology Service, Massachusetts General Hospital, Boston, Massachusetts

Disclosures

Disclosure: Panagiotis Fidias, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.
Served as a speaker or a member of a speakers bureau for: Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Genentech, Inc.

Dr Fidias does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Fidias does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Jared Weiss, MD

Assistant Professor of Medicine, Division of Hematology and Oncology, University of North Carolina School of Medicine; Attending Physician, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

Disclosures

Disclosure: Jared Weiss, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Biodesix, Inc.; Clovis Oncology; OncoPlexDx
Received grants for clinical research from: Astellas Pharma, Inc.; AstraZeneca Pharmaceuticals LP; Celgene Corporation; GlaxoSmithKline; Pfizer Inc

Dr Weiss does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Weiss does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Seattle, Washington

Disclosures

Disclosure: H. Jack West, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Celgene Corporation; Genentech, Inc.; Guardant Health, Inc.; Roche

Dr West does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr West does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Hossein Borghaei, DO

Associate Professor, Medical Oncology; Chief, Thoracic Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania

Disclosures

Disclosure: Hossein Borghaei, DO, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bristol-Myers Squibb Company; Celgene Corporation; Genentech, Inc.; Lilly
Received grants for clinical research from: Millennium Pharmaceuticals, Inc.

Dr Borghaei does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Borghaei does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor

Joanne M. Faysal, MS

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Joanne M. Faysal, MS, has disclosed no relevant financial relationships.

CME Reviewer

Amy Bernard, MS, BSN, RN-BC

Lead Nurse Planner, Medscape, LLC

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Oncology

CME

New Horizons in Advanced Non-small Cell Lung Cancer: Highlights from Chicago

Authors: Suresh S. Ramalingam, MD; Giorgio V. Scagliotti, MD, PhD; Panagiotis Fidias, MD; Jared Weiss, MD; H. Jack West, MD; Hossein Borghaei, DOFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME Released: 6/22/2015

Valid for credit through: 6/22/2016, 11:59 PM EST

processing....

Editor’s Note: On October 9, 2015, after filming of this activity, the U.S. Food and Drug Administration (FDA) expanded its approval of nivolumab for use in patients with non-squamous non-small cell lung cancer (NSCLC) whose disease has progressed during or after platinum-based chemotherapy. In addition, on November 13, 2015, the FDA granted accelerated approval to osimertinib (AZD9291) for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive NSCLC, as detected by an FDA-approved test, who have progressed on or after EGFR TKI therapy. On November 24, 2015, the U.S. FDA approved necitumumab for use in combination with gemcitabine and cisplatin in patients with metastatic squamous NSCLC who have not been previously treated. Finally, on December 11, 2015, the FDA granted an accelerated approval for alectinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic NSCLC who have progressed on or are intolerant to crizotinib.

Contents of This CME Activity

All sections of this activity are required for credit.

Section 1. Emerging Therapies in EGFR-Resistant NSCLC

Dr Ramalingam reviews the latest clinical data on emerging therapies for patients with T790M EGFR mutations.
Suresh S. Ramalingam, MD

Section 2. Current and Future Directions in the Treatment of ALK-Resistant NSCLC

Dr Scagliotti discusses the efficacy and safety of second-generation ALK inhibitors.
Giorgio V. Scagliotti, MD, PhD

Section 3. Targeting Novel Biomarkers in Advanced NSCLC

Dr Fidias reviews recent data on therapies that target the MET pathway and BRAF V600K mutations.
Panagiotis Fidias, MD

Section 4. Clinical Advances in NSCLC: Emerging Chemotherapy Options

Dr Weiss provides analysis of the latest chemotherapeutic agents in clinical trials.
Jared Weiss, MD

Section 5. Advances and Perspectives in Squamous Cell NSCLC

Dr West examines recent data on emerging therapies for the treatment of squamous cell NSCLC.
H. Jack West, MD

Section 6. Immunotherapy in NSCLC: PD-1 and PD-L1 Inhibitors

Dr Borghaei offers in-depth insight into PD-1 and PD-L1 inhibitors for advanced NSCLC.
Hossein Borghaei, DO

Educational Impact Challenge

Assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 9

CME Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Authors

Suresh S. Ramalingam, MD

Giorgio V. Scagliotti, MD, PhD

Panagiotis Fidias, MD

Jared Weiss, MD

H. Jack West, MD

Hossein Borghaei, DO

Editor

Joanne M. Faysal, MS

CME Reviewer

Amy Bernard, MS, BSN, RN-BC

Peer Reviewer

CME

New Horizons in Advanced Non-small Cell Lung Cancer: Highlights from Chicago

Target Audience and Goal Statement

Disclosures

Authors

Suresh S. Ramalingam, MD

Giorgio V. Scagliotti, MD, PhD

Panagiotis Fidias, MD

Jared Weiss, MD

H. Jack West, MD

Hossein Borghaei, DO

Editor

Joanne M. Faysal, MS

CME Reviewer

Amy Bernard, MS, BSN, RN-BC

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

New Horizons in Advanced Non-small Cell Lung Cancer: Highlights from Chicago

Contents of This CME Activity

Educational Impact Challenge